PROMUS Element™ Plus H7493911416300Recalls & reported problems
Boston Scientific Corporation · Everolimus-Eluting Platinum Chromium Coronary Stent System · Class 3
All models of PROMUS Element Plus (44)
Data updated Oct 16, 2026 from official FDA records · Editorial policy
- Adverse event reports
- 5
- Deaths reported
- 4
- Injuries reported
- 1
- Recalls naming it
- 0
Summary
The FDA's MAUDE database contains 5 adverse event reports that list this exact device (DI 08714729807957), received between Dec 16, 2016 and Feb 14, 2018 — classified as 4 deaths, 1 injury.
The most frequently reported specific device problem is “Occlusion Within Device” (4 reports).
Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 16, 2026.
Most reported problems
Device problems
- Adverse Event Without Identified Device or Use Problem5
- Occlusion Within Device4
Patient problems
- Death4
- Thrombosis4
- Myocardial Infarction2
- Chest Pain1
- Congestive Heart Failure1
- High Blood Pressure/ Hypertension1
Recent adverse event reports
The 5 most recent of 5 reports, in the reporter's own words as published by the FDA.
DeathFeb 14, 2018Occlusion Within Device; Adverse Event Without Identified Device or Use Problem; Occlusion Within Device; Adverse Event Without Identified Device or Use Problem
(B)(4) CLINICAL STUDY. IT WAS REPORTED THAT THE PATIENT DIED. IN (B)(6) 2013, THE PATIENT PRESENTED DUE TO UNSTABLE ANGINA (BRAUNWALD CLASSIFICATION: IIIB). SUBSEQUENTLY, THE PATIENT WAS REFERRED FOR CARDIAC CATHETERIZATION AND THE INDEX PROCEDURE WAS PERFORMED ON THE SAME DAY. THE TARGET LESION# 1 WAS A DE NOVO LESION LOCATED IN THE PROXIMAL LEFT ANTERIOR DESCENDING ARTERY WITH 75% STENOSIS AND WAS 10MM LONG WITH A REFERENCE VESSEL DIAMETER OF 3. 50 MM. THE LESION WAS TREATED WITH DIRECT PLACEMENT OF 3.00X16MM PROMUS ELEMENT¿ PLUS DRUG-ELUTING STENT. FOLLOWING POST DILATATION, RESIDUAL STENOSIS WAS 0%. ONE DAY POST PROCEDURE, THE PATIENT WAS DISCHARGED ON ASPIRIN AND CLOPIDOGREL. IN (B)(6) 2017, THE PATIENT EXPIRED. PER DEATH CERTIFICATE, THE PATIENT DIED DUE TO ATHEROSCLEROTIC HEART DISEASE. THE OTHER SIGNIFICANT CONDITIONS CONTRIBUTING TO THE DEATH OF THE PATIENT WERE CONGESTIVE HEART FAILURE, ATRIAL FIBRILLATION AND HYPERTENSION. AUTOPSY WAS NOT PERFORMED.
Patient problems: Death; Thrombosis
MAUDE report 7271892 ↗DeathSep 18, 2017Occlusion Within Device; Adverse Event Without Identified Device or Use Problem; Occlusion Within Device; Adverse Event Without Identified Device or Use Problem
(B)(6) CLINICAL STUDY. SAME CASE AS: 2134265-2017-09093 AND 2134265-2017-09097. IT WAS REPORTED THAT THE PATIENT EXPIRED. IN (B)(6) 2012 THE PATIENT PRESENTED WITH UNSTABLE ANGINA AND WAS REFERRED FOR CARDIAC CATHETERIZATION. CORONARY ANGIOGRAPHY WAS PERFORMED AND THE PATIENT WAS REFERRED FOR PERCUTANEOUS CORONARY INTERVENTION. TARGET LESION #1 WAS LOCATED IN THE 1ST DIAGONAL WITH 90% STENOSIS AND WAS 10 MM LONG WITH A REFERENCE VESSEL DIAMETER OF 3.00 MM. TARGET LESION #1 WAS TREATED WITH DIRECT PLACEMENT USING 3.00 MM X 12.00 MM PROMUS ELEMENT¿ PLUS STENT, FOLLOWING POST DILATATION WITH 0% RESIDUAL STENOSIS. TARGET LESION #2 WAS LOCATED IN THE PROXIMAL LCX WITH 90% STENOSIS AND WAS 10 MM LONG WITH A REFERENCE VESSEL DIAMETER OF 2.7 MM. TARGET LESION #2 WAS TREATED WITH DIRECT STENT PLACEMENT USING A 2.75 MM X 12.00 MM PROMUS ELEMENT¿ PLUS STENT FOLLOWING POST DILATATION WITH 0% RESIDUAL STENOSIS. TARGET LESION #3 WAS LOCATED IN THE DISTAL LCX WITH 60% STENOSIS AND WAS 12 MM LONG WITH A REFERENCE VESSEL DIAMETER OF 3.00 MM. TARGET LESION #3 WAS TREATED WITH DIRECT STENT PLACEMENT USING A 3.00 X 16.00 MM PROMUS ELEMENT¿ PLUS STENT. FOLLOWING POST DILATATION, RESIDUAL STENOSIS WAS 0
Patient problems: Death; Thrombosis
MAUDE report 6872457 ↗DeathMar 17, 2017Occlusion Within Device; Adverse Event Without Identified Device or Use Problem; Occlusion Within Device; Adverse Event Without Identified Device or Use Problem
IT WAS FURTHER REPORTED THAT STENT THROMBOSIS OCCURRED AS PER THE ACADEMIC RESEARCH CONSORTIUM DEFINITIONS.
Patient problems: Death; High Blood Pressure/ Hypertension; Myocardial Infarction; Thrombosis
MAUDE report 6414403 ↗InjuryMar 17, 2017Adverse Event Without Identified Device or Use Problem; Adverse Event Without Identified Device or Use Problem
IT WAS FURTHER REPORTED THAT THE STUDY STENT IN THE PROXIMAL LAD WAS PATENT. THEREFORE, THE EVENTS OCCURRED ARE NOT RELATED TO THE STUDY DEVICE.
Patient problems: Chest Pain; Myocardial Infarction
MAUDE report 6414342 ↗DeathDec 16, 2016Occlusion Within Device; Adverse Event Without Identified Device or Use Problem; Occlusion Within Device; Adverse Event Without Identified Device or Use Problem
IT WAS FURTHER REPORTED THAT DURING THE INDEX PROCEDURE, PRE-DILATATION WAS PERFORMED IN THE LEFT MAIN CORONARY ARTERY. AS PER DEATH CERTIFICATE, THE IMMEDIATE CAUSE OF DEATH WAS "CORONARY ARTERY DISEASE" AND THE SEQUENTIAL CONTRIBUTING CAUSE OF DEATH WAS "CONGESTIVE HEART FAILURE". ALSO, ADJUDICATION INDICATES STENT THROMBOSIS OCCURRED.
Patient problems: Congestive Heart Failure; Death; Thrombosis
MAUDE report 6181459 ↗
Other Coronary drug-eluting stent devices
- SYNERGY™ H7493926038300Boston Scientific Corporation · Coronary drug-eluting stent8 deaths124 reports
- SYNERGY™ H7493926016300Boston Scientific Corporation · Coronary drug-eluting stent7 deaths106 reports
- SYNERGY™ H7493926020300Boston Scientific Corporation · Coronary drug-eluting stent9 deaths90 reports
- XIENCE Sierra™ 1550350-33Abbott Vascular Inc. · Coronary drug-eluting stent1 recall32 reports
- SYNERGY™ H7493926016250Boston Scientific Corporation · Coronary drug-eluting stent6 deaths82 reports
- Resolute Onyx™ RONYX30022UXMedtronic, Inc. · Coronary drug-eluting stent6 deaths76 reports
- SYNERGY™ H7493926024300Boston Scientific Corporation · Coronary drug-eluting stent3 deaths75 reports
- Resolute Onyx™ RONYX30015UXMedtronic, Inc. · Coronary drug-eluting stent3 deaths73 reports
Sources and updates
- Device record: FDA GUDID, file dated Oct 13, 2026 · View this device in AccessGUDID ↗
- Adverse event reports: FDA MAUDE, file dated Oct 14, 2026 · each report above links to its original FDA record
- Recalls: FDA Medical Device Recalls, file dated Oct 16, 2026
- Page last rebuilt: Oct 16, 2026. Data downloaded through openFDA, which notes it is not validated for clinical or regulatory use.
How reports and recalls are matched · Editorial policy · Report an error on this page